[Pathophysiological principles of dyslipoproteinaemia]

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Atherosclerosis Pathophysiology

Background:

• Atherosclerotic cardiovascular disease (ASCVD) risk has been reduced by lowering atherogenic lipoproteins.
• Cardiovascular disease remains the leading global cause of mortality.
• Lipid and lipoprotein metabolism changes are clinically significant in ASCVD.

Purpose of the Study:

• To review the clinical significance of lipid and lipoprotein metabolism pathophysiology.
• To highlight the role of elevated atherogenic lipoproteins as a causal risk factor for ASCVD.
• To discuss primary and secondary dyslipidemias in relation to ASCVD risk.

Main Methods:

• Review of current literature on lipid metabolism and cardiovascular disease.
• Analysis of the pathophysiological mechanisms underlying lipid disorders.
• Identification of key regulatory steps in lipid metabolism as drug targets.

Main Results:

• Elevated atherogenic lipoproteins are a primary cause of ASCVD.
• Primary hypercholesterolemia confers a higher ASCVD risk due to lifelong LDL elevation.
• Secondary lipid metabolism changes (e.g., in diabetes, hypothyroidism) require identification and treatment.

Conclusions:

• Effective lipid management has significantly impacted cardiovascular health.
• Further research into lipid metabolism pathophysiology is crucial for novel therapeutic strategies.
• Targeting key regulatory steps in lipid metabolism offers potential for new treatments against atherosclerotic plaque.